Summary:

• Biocon Biologics will introduce three new oncology biosimilars — for Trastuzumab/Hyaluronidase (Herceptin SC/Herceptin HYLECTA), Nivolumab (Opdivo) and Pembrolizumab (Keytruda) — at the 2026 J.P. Morgan Healthcare Conference, significantly broadening its cancer portfolio​

• These assets target blockbuster markets: 2024 global sales were about US$29.5 billion for Keytruda, US$9.3 billion for Opdivo and US$1.72 billion combined for Herceptin SC/Herceptin HYLECTA, and they will sit alongside 17 existing oncology medicines including a Pertuzumab (Perjeta) biosimilar already filed with the US FDA​

• The company estimates its oncology franchise, including undisclosed products, addresses more than US$75 billion of market opportunity, or roughly 35% of the global oncology pharma market​

• Biocon Limited plans to integrate Biocon Biologics as a wholly owned subsidiary by 31 March 2026, creating a combined business positioned as the only player offering both biosimilar insulins and complex peptide generics such as GLP‑1s across the full diabetes-care spectrum​

• Post‑integration, Biocon aims to strengthen its presence in diabetes, oncology and immunology — therapeutic areas that together represent nearly 40% of global pharmaceutical revenues — while leveraging Biocon Biologics’ commercial infrastructure serving over 6 million patients in more than 120 markets​

• Upon completion and regulatory approvals, Shreehas Tambe will become CEO and Managing Director of the integrated business and will outline the strategic roadmap in presentations and fireside chats at the J.P. Morgan and Endpoints JPM26 conferences​